CG Invites Co., Ltd. (KOSDAQ:083790)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,644.00
-65.00 (-3.80%)
Aug 1, 2025, 3:30 PM KST
-3.80%
Market Cap126.41B
Revenue (ttm)9.62B
Net Income (ttm)-48.80B
Shares Out76.89M
EPS (ttm)-635.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume219,586
Average Volume138,453
Open1,688.00
Previous Close1,709.00
Day's Range1,621.00 - 1,705.00
52-Week Range1,621.00 - 2,795.00
Beta0.38
RSI29.01
Earnings DateAug 13, 2025

About Exscientia

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 83
Stock Exchange KOSDAQ
Ticker Symbol 083790
Full Company Profile

Financial Performance

In 2024, CG Invites's revenue was 7.25 billion, an increase of 48.67% compared to the previous year's 4.88 billion. Losses were -51.54 billion, 5.36% more than in 2023.

Financial numbers in EUR Financial Statements

News

There is no news available yet.